Engineering CRISPR/Cas9 therapeutics for cancer precision medicine

Area of Science:

• Genomic Medicine
• Molecular Oncology
• Biotechnology

Background:

• The discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology has significantly advanced cancer research and treatment.
• Understanding cancer biology, including key genetic alterations and signaling pathways, is crucial for developing targeted therapies.

Purpose of the Study:

• To review the application of CRISPR/Cas9 technology in editing and investigating genes involved in human carcinogenesis.
• To explore recent advancements in CRISPR/Cas9 systems for targeting oncogenic genes and developing personalized cancer therapies.
• To provide insights into CRISPR-based approaches for cancer biomarker identification and drug discovery.

Main Methods:

• Review of existing literature and preclinical studies on CRISPR/Cas9 applications in cancer.
• Analysis of CRISPR/Cas9 system design for targeting oncogenes and modulating the tumor microenvironment.
• Exploration of high-throughput CRISPR screening for biomarker discovery and drug development.

Main Results:

• CRISPR/Cas9 demonstrates utility in disrupting oncogenic targets and enhancing existing anti-cancer treatments.
• CRISPR technology facilitates the modulation of the tumor microenvironment for improved therapeutic efficacy.
• CRISPR-based screens are effective for identifying cancer biomarkers and accelerating drug discovery.

Conclusions:

• CRISPR/Cas9 technology offers transformative potential for developing innovative and effective cancer therapeutics.
• Engineering CRISPR/Cas9 systems enables tailored approaches to address specific genetic aberrations in cancer.
• The review underscores the significant impact of CRISPR/Cas9 on the future of cancer treatment and personalized medicine.